Overview Dividends

(RYTM) Rhythm Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US76243J1051

Setmelanotide, Rare Obesity, MC4R Agonist, Commercial-Stage

Biotechnology
Market Cap in USD: 7,465m
IPO / Inception: 2017-10-05
Return 12m vs S&P 500: 71.0%

EPS (Earnings per Share)

EPS (Earnings per Share) of RYTM over the last years for every Quarter: "2020-12": -0.79, "2021-03": -1.16, "2021-06": -0.7, "2021-09": -0.7, "2021-12": -0.85, "2022-03": -1.05, "2022-06": -0.89, "2022-09": -0.79, "2022-12": -0.75, "2023-03": -0.92, "2023-06": -0.82, "2023-09": -0.76, "2023-12": -0.7, "2024-03": -2.35, "2024-06": -0.69, "2024-09": -0.73, "2024-12": -0.72, "2025-03": -0.81, "2025-06": -0.75, "2025-09": -0.82,
EPS CAGR: 0.50%
EPS Trend: 9.2%
Last SUE: -0.27
Qual. Beats: 0

Revenue

Revenue of RYTM over the last years for every Quarter: 2020-12: 0, 2021-03: 0.035, 2021-06: 0.274, 2021-09: 1.028, 2021-12: 1.817, 2022-03: 1.498, 2022-06: 9.066, 2022-09: 4.284, 2022-12: 8.79, 2023-03: 11.469, 2023-06: 19.221, 2023-09: 22.504, 2023-12: 24.234, 2024-03: 25.967, 2024-06: 29.078, 2024-09: 33.251, 2024-12: 41.83, 2025-03: 32.704, 2025-06: 48.502, 2025-09: 51.298,
Rev. CAGR: 143.71%
Rev. Trend: 80.0%
Last SUE: 0.16
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 53.1%
Value at Risk 5%th 77.9%
Relative Tail Risk -10.76%
Reward TTM
Sharpe Ratio 1.40
Alpha 86.53
CAGR/Max DD 1.04
Character TTM
Hurst Exponent 0.597
Beta 0.668
Beta Downside 0.949
Drawdowns 3y
Max DD 53.83%
Mean DD 18.26%
Median DD 14.72%

Description: RYTM Rhythm Pharmaceuticals November 06, 2025

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharma focused on rare neuroendocrine disorders, most notably obesity driven by genetic defects in the melanocortin-4 (MC4R) pathway.

Its flagship product, IMCIVREE (setmelanotide), is already FDA-approved for obesity linked to POMC, LEPR, and Bardet-Biedl/Alström syndromes, and is now in Phase 3 trials expanding into heterozygous POMC/LEPR deficiency, SRC-1 deficiency, SH2B1 deficiency, MC4R deficiency, and other MC4R-related conditions.

Rhythm maintains a network of licensing and collaboration agreements-including with LG Chem, Ipsen, Camurus, RareStone, and Axovia Therapeutics-to broaden setmelanotide’s global reach and co-develop pipeline assets.

Key financial and market metrics (FY 2023): revenue of $58 million driven by IMCIVREE sales, a net loss of $210 million reflecting heavy R&D spend, and cash & equivalents of $550 million providing roughly 18 months of runway at current burn rates. The rare-obesity market is estimated at $3–4 billion globally, growing at ~7% CAGR, and setmelanotide’s pricing (≈$30,000–$40,000 per patient annually) positions it among the higher-margin specialty therapies.

For a deeper quantitative view of RYTM’s valuation metrics, you may find ValueRay’s analyst dashboard useful.

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income (-192.3m TTM) > 0 and > 6% of Revenue (6% = 10.5m TTM)
FCFTA -0.22 (>2.0%) and ΔFCFTA 23.69pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 224.0% (prev 215.7%; Δ 8.31pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.22 (>3.0%) and CFO -109.1m > Net Income -192.3m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 4.75 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (64.3m) change vs 12m ago 5.11% (target <= -2.0% for YES)
Gross Margin 89.40% (prev 88.61%; Δ 0.79pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 40.06% (prev 30.95%; Δ 9.11pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -7.96 (EBITDA TTM -169.0m / Interest Expense TTM 21.4m) >= 6 (WARN >= 3)

Altman Z'' -9.79

(A) 0.77 = (Total Current Assets 494.8m - Total Current Liabilities 104.3m) / Total Assets 506.9m
(B) -2.57 = Retained Earnings (Balance) -1.30b / Total Assets 506.9m
warn (B) unusual magnitude: -2.57 — check mapping/units
(C) -0.39 = EBIT TTM -170.5m / Avg Total Assets 435.2m
(D) -3.65 = Book Value of Equity -1.31b / Total Liabilities 358.1m
Total Rating: -9.79 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 42.21

1. Piotroski 2.0pt
2. FCF Yield -1.52%
3. FCF Margin -62.60%
4. Debt/Equity 1.01
5. Debt/Ebitda -0.59
7. RoE -165.6%
8. Rev. Trend 79.98%
9. EPS Trend 9.17%

What is the price of RYTM shares?

As of December 27, 2025, the stock is trading at USD 112.27 with a total of 228,112 shares traded.
Over the past week, the price has changed by +0.48%, over one month by +3.24%, over three months by +13.24% and over the past year by +98.57%.

Is RYTM a buy, sell or hold?

Rhythm Pharmaceuticals has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy RYTM.
  • Strong Buy: 8
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the RYTM price?

Issuer Target Up/Down from current
Wallstreet Target Price 138.1 23%
Analysts Target Price 138.1 23%
ValueRay Target Price 174.2 55.2%

RYTM Fundamental Data Overview December 27, 2025

Market Cap USD = 7.47b (7.47b USD * 1.0 USD.USD)
P/S = 42.8207
P/B = 50.1629
Beta = 1.967
Revenue TTM = 174.3m USD
EBIT TTM = -170.5m USD
EBITDA TTM = -169.0m USD
Long Term Debt = 4.14m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 624.0k USD (from shortTermDebt, last quarter)
Debt = 151.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 98.9m USD (from netDebt column, last quarter)
Enterprise Value = 7.20b USD (7.47b + Debt 151.0m - CCE 416.1m)
Interest Coverage Ratio = -7.96 (Ebit TTM -170.5m / Interest Expense TTM 21.4m)
FCF Yield = -1.52% (FCF TTM -109.1m / Enterprise Value 7.20b)
FCF Margin = -62.60% (FCF TTM -109.1m / Revenue TTM 174.3m)
Net Margin = -110.3% (Net Income TTM -192.3m / Revenue TTM 174.3m)
Gross Margin = 89.40% ((Revenue TTM 174.3m - Cost of Revenue TTM 18.5m) / Revenue TTM)
Gross Margin QoQ = 89.28% (prev 88.57%)
Tobins Q-Ratio = 14.20 (Enterprise Value 7.20b / Total Assets 506.9m)
Interest Expense / Debt = 3.14% (Interest Expense 4.74m / Debt 151.0m)
Taxrate = -0.21% (negative due to tax credits) (111.0k / -52.8m)
NOPAT = -170.8m (EBIT -170.5m * (1 - -0.21%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 4.75 (Total Current Assets 494.8m / Total Current Liabilities 104.3m)
Debt / Equity = 1.01 (Debt 151.0m / totalStockholderEquity, last quarter 148.8m)
Debt / EBITDA = -0.59 (negative EBITDA) (Net Debt 98.9m / EBITDA -169.0m)
Debt / FCF = -0.91 (negative FCF - burning cash) (Net Debt 98.9m / FCF TTM -109.1m)
Total Stockholder Equity = 116.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.94% (Net Income -192.3m / Total Assets 506.9m)
RoE = -165.6% (Net Income TTM -192.3m / Total Stockholder Equity 116.1m)
RoCE = -141.7% (out of range, set to none) (EBIT -170.5m / Capital Employed (Equity 116.1m + L.T.Debt 4.14m))
RoIC = -384.8% (out of range, set to none) (NOPAT -170.8m / Invested Capital 44.4m)
WACC = 8.37% (E(7.47b)/V(7.62b) * Re(8.48%) + D(151.0m)/V(7.62b) * Rd(3.14%) * (1-Tc(-0.00)))
Discount Rate = 8.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.25%
Fair Price DCF = unknown (Cash Flow -109.1m)
EPS Correlation: 9.17 | EPS CAGR: 0.50% | SUE: -0.27 | # QB: 0
Revenue Correlation: 79.98 | Revenue CAGR: 143.7% | SUE: 0.16 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.79 | Chg30d=+0.004 | Revisions Net=+1 | Analysts=7
EPS next Year (2026-12-31): EPS=-2.62 | Chg30d=-0.209 | Revisions Net=-2 | Growth EPS=+15.1% | Growth Revenue=+55.6%

Additional Sources for RYTM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle